ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Inclusion Criteria:

• Documented TTR mutation

• Amyloid deposits in cardiac or non-cardiac tissue

• Medical history of heart failure

• Evidence of cardiac involvement by echocardiogram

Exclusion Criteria:

• Has known primary amyloidosis (AL), leptomeningeal amyloidosis, non-FAC hereditarycardiomyopathy, hypertensive cardiomyopathy, or cardiomyopathy due to valvular heartdisease

• Has known peripheral vascular disease affecting ambulation

• Has a Polyneuropathy Disability score >2

• Has a New York Heart Association (NYHA) classification of IV